A Phase 1 interventional study of Caffeine and ABX464 in Healthy, sponsored by Abivax S.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Abivax S.A. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs
This is a Phase 1, 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine) and a known CYP1A2 inhibitor (fluvoxamine). Up to sixty (60) healthy adult male and female subjects 18 to 55 years of age are planned to participate in the study. Separate cohorts of subjects will be enrolled for Part A (up to 24 subjects enrolled to allow 22 subjects required to complete Part A ) and Part B (up to 36 subjects enrolled to allow 32 subjects were to complete Part B).
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Experiences regular headaches (i.e., experiences headaches more than weekly).
Part B Only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days). Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.
Drug: Caffeine · Drug: ABX464
Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days). ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2
Drug: ABX464 · Drug: Fluvoxamine
This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).
This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
Part A - Day 1 Peak Plasma Concentration of Caffeine
Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
Time frame: Day 1
Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464
Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
Time frame: Day 4
Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464
Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
Time frame: Day 17
Part A - Day 1 AUC of Caffeine
Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
Time frame: Day 1
Part A - Day 4 AUC of Caffeine & ABX464
Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
Time frame: Day 4
Part A - Day 17 AUC of Caffeine & ABX464
Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
Time frame: Day 17
Part B - Day 1 - Peak Plasma Concentration of ABX464
Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5,5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
Time frame: Day 1
Part B - Day 11 - Peak Plasma Concentration of ABX464
Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h.Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
Time frame: Day 11
Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)
Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
Time frame: Day 1
Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)
Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
Time frame: Day 11
Number of Adverse Events (AEs)
Number of Adverse Events (AEs): Parts A \& B safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamine
Time frame: From baseline up to Day 25
Study recruitment for this study was undertaken in South Wales in the United Kingdom. The recruitment process began in December 2020 and concluded in April 2021. 164 subjects were screened in order to successfully recruit 59 eligible participants.
| Milestone | Part A- Caffeine First, Then ABX64 With and Without Caffeine, Followed by ABX64 With Caffeine | Part B-ABX64 First, Then Fluvoxamine, Followed by ABX64 With Fluvoxamine" |
|---|---|---|
| Started | 24 | 35 |
| Completed | 24 | 34 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
| ng/mL | Part A - PK Analysis Set |
|---|---|
| Part A - Day 1 Peak Plasma Concentration of Caffeine | 931 ± 285 |
Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
| ng/mL | Part A - PK Analysis Set |
|---|---|
| Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464 | 930 ± 278 |
Peak Plasma Concentration (Cmax) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
| ng/mL | Part A - PK Analysis Set |
|---|---|
| Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464 | 564 ± 242 |
Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
| h*ng/mL | Part A - PK Analysis Set |
|---|---|
| Part A - Day 1 AUC of Caffeine | 7420 ± 4760 |
Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
| h*ng/mL | Part A - PK Analysis Set |
|---|---|
| Part A - Day 4 AUC of Caffeine & ABX464 | 5460 ± 2740 |
Area under the plasma concentration versus time curve (AUC) for caffeine as measured by PK plasma sampling at t pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 18, 24, 36 and 48h. Timepoints were relative to dosing Days 1 (caffeine only), Day 4 (caffeine and ABX464) and Day 17 (caffeine and ABX464).
| h*ng/mL | Part A - PK Analysis Set |
|---|---|
| Part A - Day 17 AUC of Caffeine & ABX464 | 1560 ± 719 |
Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5,5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
| ng/mL | Part B PK Analysis Set |
|---|---|
| Part B - Day 1 - Peak Plasma Concentration of ABX464 | 23.2 ± 12.5 |
Peak Plasma Concentration (Cmax) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h.Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
| ng/mL | Part B PK Analysis Set |
|---|---|
| Part B - Day 11 - Peak Plasma Concentration of ABX464 | 33.4 ± 19.0 |
Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
| h*ng/mL | Part B PK Analysis Set |
|---|---|
| Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC) | 55.2 ± 25.7 |
Area under the plasma concentration versus time curve (AUC) for ABX464 as measured by PK plasma sampling at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12h. Timepoints were relative to dosing Days 1 (ABX464 only) and Day 11 (ABX464 and fluvoxamine).
| h*ng/mL | Part B PK Analysis Set |
|---|---|
| Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC) | 73.0 ± 34.2 |
Number of Adverse Events (AEs): Parts A \& B safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamine
| Participants | Part A Participants - Safety Analysis Set | Part B Participants - Safety Analysis Set |
|---|---|---|
| Number of Adverse Events (AEs) | 16 | 30 |
Collected over Adverse events were reported throughout the study from Day -1 until completion of the post study follow up visit (approximately 9 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A- Caffeine Only (Day 1) | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| Part A - Caffeine and ABX464 (Day 4) | 0/24 (0%) | 0/24 (0%) | 10/24 (41.7%) |
| Part A - ABX464 Only (Days 5-16) | 0/24 (0%) | 0/24 (0%) | 14/24 (58.3%) |
| Part A - Caffeine and ABX464 (Day 17) | 0/24 (0%) | 0/24 (0%) | 3/24 (12.5%) |
| Part A Overall | 0/24 (0%) | 0/24 (0%) | 16/24 (66.7%) |
| Part B - ABX464 Only (Day 1) | 0/35 (0%) | 0/35 (0%) | 23/35 (65.7%) |
| Part B - Fluvoxamine Only (Days 2-10) | 0/35 (0%) | 0/35 (0%) | 24/35 (68.6%) |
| Part B - ABX464 and Fluvoxamine (Day 11) | 0/34 (0%) | 0/34 (0%) | 21/34 (61.8%) |
| Part B - Fluvoxamine Only (Days 12-25) | 0/34 (0%) | 0/34 (0%) | 11/34 (32.4%) |
| Part B Overall | 0/35 (0%) | 0/35 (0%) | 30/35 (85.7%) |
| Event | Part A- Caffeine Only (Day 1) | Part A - Caffeine and ABX464 (Day 4) | Part A - ABX464 Only (Days 5-16) | Part A - Caffeine and ABX464 (Day 17) | Part A Overall | Part B - ABX464 Only (Day 1) | Part B - Fluvoxamine Only (Days 2-10) | Part B - ABX464 and Fluvoxamine (Day 11) | Part B - Fluvoxamine Only (Days 12-25) | Part B Overall |
|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/24 | 8/24 | 13/24 | 1/24 | 13/24 | 21/35 | 1/35 | 17/34 | 3/34 | 25/35 |
| NauseaGastrointestinal disorders | 0/24 | 6/24 | 1/24 | 1/24 | 7/24 | 10/35 | 10/35 | 10/34 | 1/34 | 20/35 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/24 | 0/24 | 1/24 | 0/24 | 1/24 | 0/35 | 14/35 | 1/34 | 0/34 | 15/35 |
| FatigueGeneral disorders | 0/24 | 0/24 | 3/24 | 0/24 | 3/24 | 0/35 | 13/35 | 0/34 | 1/34 | 14/35 |
| VomitingGastrointestinal disorders | 0/24 | 2/24 | 0/24 | 0/24 | 2/24 | 8/35 | 2/35 | 6/34 | 0/34 | 11/35 |
| InsomniaPsychiatric disorders | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 1/35 | 8/35 | 0/34 | 1/34 | 8/35 |
| LethargyGeneral disorders | 0/24 | 0/24 | 3/24 | 0/24 | 3/24 | 0/35 | 2/35 | 0/34 | 0/34 | 2/35 |
| DizzinessNervous system disorders | 0/24 | 1/24 | 0/24 | 1/24 | 2/24 | 0/35 | 3/35 | 0/34 | 0/34 | 3/35 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 0/24 | 1/24 | 0/24 | 1/24 | 0/35 | 1/35 | 0/34 | 1/34 | 2/35 |
| FlatulenceGastrointestinal disorders | 0/24 | 0/24 | 1/24 | 0/24 | 1/24 | 1/35 | 1/35 | 0/34 | 0/34 | 2/35 |
This baseline analysis population corresponds to the number of participants included within the Safety Analysis set population for the study for each respective part.
| Age, Categorical(Participants) | Part A & Part B |
|---|---|
| Part A — <=18 years | 0 |
| Part A — Between 18 and 65 years | 24 |
| Part A — >=65 years | 0 |
| Part B — <=18 years | 0 |
| Part B — Between 18 and 65 years | 35 |
| Part B — >=65 years | 0 |
| Age, Continuous(Years) | Part A & Part B |
|---|---|
| Part A | 33.7 ± 9.44 |
| Part B | 36.8 ± 9.75 |
| Sex: Female, Male(Participants) | Part A & Part B |
|---|---|
| Part A — Female | 5 |
| Part A — Male | 19 |
| Part B — Female | 13 |
| Part B — Male | 22 |
| Race and Ethnicity Not Collected(Participants) | Part A & Part B |
|---|
| Region of Enrollment(participants) | Part A & Part B |
|---|---|
| United Kingdom | 59 |
| Screening Weight(Kilograms) | Part A & Part B |
|---|---|
| Part A | 78.86 ± 12.473 |
| Part B | 78.60 ± 15.810 |
| Height(Metres) | Part A & Part B |
|---|---|
| Part A | 1.758 ± 0.0923 |
| Part B | 1.738 ± 0.1021 |
| Body Mass Index(kg/m^2) | Part A & Part B |
|---|---|
| Part A | 25.379 ± 2.4786 |
| Part B | 25.743 ± 2.7545 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in May 2021, 5 months.
Results were first posted in Nov 2026, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: ABX464 · Fluvoxamine